Entity Central Index Key Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Shell Company Entity Shell Company Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, Address Line Two Entity Address Address Line2 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report The total amount due to the entity within one year of the balance sheet date (or one operating cycle, if longer) from outside sources, including amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer. as well as trade accounts receivable, notes and loans receivable. Statement Of Financial Position [Abstract] Assets Assets [Abstract] Current assets: Assets Current [Abstract] Cash and cash equivalents Cash And Cash Equivalents At Carrying Value Accounts receivable Accounts Receivable Net Current Prepaid expenses and other current assets Prepaid Expenses And Other Receivables Total current assets Assets Current Property and equipment, net Property Plant And Equipment Net Operating lease right-of-use asset, net Operating Lease Right Of Use Asset Equity-method investment Equity Method Investments Non-current restricted cash Restricted Cash Noncurrent Total assets Assets Liabilities and stockholders’ equity Liabilities And Stockholders Equity [Abstract] Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Deferred revenue Deferred Revenue Current Total current liabilities Liabilities Current Deferred revenue, net of current portion Deferred Revenue Noncurrent Long-term debt Long Term Debt Noncurrent Operating lease liability, net of current portion Operating Lease Liability Noncurrent Deferred rent Deferred Rent Credit Noncurrent Total liabilities Liabilities Stockholders’ equity Stockholders Equity [Abstract] Common stock: $0.001 par value; 30,000 shares authorized; 15,126 issued and outstanding at September 30, 2019; NIS 0.07 par value; 30,000 shares authorized, 10,762 issued, 10,719 outstanding and 43 held in treasury at December 31, 2018 Common Stock Value Additional paid-in capital Additional Paid In Capital Accumulated deficit Retained Earnings Accumulated Deficit Total stockholders’ equity Stockholders Equity Total liabilities and stockholders’ equity Liabilities And Stockholders Equity Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Treasury shares Treasury Stock Common Shares Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Statement Of Income And Comprehensive Income [Abstract] Collaboration revenue Revenue From Contract With Customer Excluding Assessed Tax Operating expenses: Operating Expenses [Abstract] Research and development, net Research And Development Expense General and administrative General And Administrative Expense Total operating expenses Operating Expenses Loss from operations Operating Income Loss Gain (loss) from equity-method investment Income Loss From Equity Method Investments Finance (expense) income, net Other Nonoperating Income Expense Net loss Net Income Loss Net loss per share, basic and diluted Earnings Per Share Basic And Diluted Weighted-average shares outstanding, basic and diluted Weighted Average Number Of Share Outstanding Basic And Diluted Comprehensive loss: Comprehensive Income Net Of Tax [Abstract] Net loss Unrealized gain on short-term investments Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Comprehensive loss Comprehensive Income Net Of Tax Stock issued during period value, redomiciliation share exchange. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Additional Paid-In Capital [Member] Additional Paid In Capital [Member] Accumulated Other Comprehensive (Loss) Gain [Member] Accumulated Other Comprehensive Income [Member] Accumulated Deficit [Member] Retained Earnings [Member] Statement [Line Items] Statement [Line Items] Balance Balance (in shares) Shares Outstanding Treasury stock Stock Repurchased During Period Value Treasury stock (in shares) Stock Repurchased During Period Shares Share-based compensation Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Redomiciliation share exchange Stock Issued During Period Value Redomiciliation Share Exchange Issuance of restricted common stock and option, net of issuance costs Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures Issuance of restricted common stock and option, net of issuance costs (in shares) Stock Issued During Period Shares Restricted Stock Award Net Of Forfeitures Issuance of common stock, net of issuance costs Stock Issued During Period Value New Issues Issuance of common stock, net of issuance costs (in shares) Stock Issued During Period Shares New Issues Issuance of common stock upon exercise of stock options Stock Issued During Period Value Stock Options Exercised Issuance of common stock upon exercise of stock option (in shares) Stock Issued During Period Shares Stock Options Exercised Effect of adoption of ASU 2014-09 Cumulative Effect On Retained Earnings Tax1 Balance Balance (in shares) Operating lease right-of-use asset, amortization. Non Cash Interest Expenses. Statement Of Cash Flows [Abstract] OPERATING ACTIVITIES: Net Cash Provided By Used In Operating Activities [Abstract] Adjustments to reconcile net loss to net cash provided by (used in) operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Amortization of right-of-use operating lease asset Operating Lease Right Of Use Asset Amortization Share-based compensation expense Share Based Compensation Non-cash interest expense Non Cash Interest Expenses Changes in operating assets and liabilities Increase Decrease In Operating Capital [Abstract] Accounts receivable Increase Decrease In Accounts Receivable Prepaid expense and other assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Deferred revenue Increase Decrease In Contract With Customer Liability Net cash provided by (used in) operating activities Net Cash Provided By Used In Operating Activities INVESTING ACTIVITIES: Net Cash Provided By Used In Investing Activities [Abstract] Proceeds from maturities of short-term investments Proceeds From Maturities Prepayments And Calls Of Shortterm Investments Purchases of short-term investments Payments To Acquire Short Term Investments Acquisition of property and equipment Payments To Acquire Property Plant And Equipment Net cash (used in) provided by investing activities Net Cash Provided By Used In Investing Activities FINANCING ACTIVITIES: Net Cash Provided By Used In Financing Activities [Abstract] Proceeds from the issuance of restricted common stock and option, net of issuance costs Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Proceeds from the issuance of common stock, net of issuance costs Proceeds From Issuance Of Common Stock Proceeds from exercise of stock options Proceeds From Stock Options Exercised Net cash provided by financing activities Net Cash Provided By Used In Financing Activities NET INCREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash, cash equivalents and restricted cash at beginning of the period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Cash, cash equivalents and restricted cash at end of the period Sale of intangible assets for equity method investment. Release of repurchase liability for restricted shares. Supplemental disclosure of cash flow information Supplemental Cash Flow Information [Abstract] Cash paid for interest Interest Paid Net Non-cash investing activities Cash Flow Noncash Investing And Financing Activities Disclosure [Abstract] Right-of-use asset obtained in exchange for lease liabilities Right Of Use Asset Obtained In Exchange For Operating Lease Liability Sale of intangible assets for equity investment Sale Of Intangible Assets For Equity Method Investment Release of repurchase liability for restricted shares Release Of Repurchase Liability For Restricted Shares Purchase of property and equipment in accounts payable Capital Expenditures Incurred But Not Yet Paid Accounting Policies [Abstract] Description of Business, Basis of Presentation and Summary of Significant Accounting Policies Organization Consolidation Basis Of Presentation Business Description And Accounting Policies [Text Block] Collaboration agreements. Collaboration Agreements [Abstract] Collaboration Revenue Collaborative Arrangement Disclosure [Text Block] Fair Value Disclosures [Abstract] Fair Value Measurements Fair Value Disclosures [Text Block] Balance Sheet Related Disclosures [Abstract] Balance Sheet Details Supplemental Balance Sheet Disclosures [Text Block] Debt Disclosure [Abstract] Debt Debt Disclosure [Text Block] Stockholders Equity Note [Abstract] Stockholders' Equity Stockholders Equity Note Disclosure [Text Block] Disclosure Of Compensation Related Costs Sharebased Payments [Abstract] Share-Based Compensation Disclosure Of Compensation Related Costs Share Based Payments [Text Block] Leases [Abstract] Leases Lessee Operating Leases [Text Block] Related Party Transactions [Abstract] Related Party Transactions Related Party Transactions Disclosure [Text Block] Subsequent Events [Abstract] Subsequent Events Subsequent Events [Text Block] Basis of Presentation Consolidation Policy [Text Block] Liquidity. Liquidity Liquidity Policy Policy [Text Block] Recent developments policy. Recent Developments Recent Developments Policy Policy [Text Block] Segment Information Segment Reporting Policy Policy [Text Block] Revenue Recognition Revenue Recognition Policy [Text Block] Leases Lessee Leases Policy [Text Block] Research and Development, net Research And Development Expense Policy Statement of Cash Flows Inventory Cash Flow Policy Net Loss per Share Earnings Per Share Policy [Text Block] Recently Adopted Accounting Pronouncements New Accounting Pronouncements Policy Policy [Text Block] Schedule of Cash and Cash Equivalents and Restricted Cash Schedule Of Cash And Cash Equivalents Table [Text Block] Summary of Changes in Balances of Contract Assets and Contract Liability Contract With Customer Asset And Liability Table [Text Block] Schedule of collaboration revenue. Summary of Collaboration Revenue Schedule Of Collaboration Revenue Table [Text Block] Schedule of prepaid expenses and other current assets. Schedule of Prepaid Expenses and Other Current Assets Schedule Of Prepaid Expenses And Other Current Assets Table [Text Block] Summary of Components of Property and Equipment, Net Property Plant And Equipment [Text Block] Schedule of Accrued Liabilities Schedule Of Accrued Liabilities Table [Text Block] Schedule of Share-based Compensation Expenses Schedule Of Compensation Cost For Share Based Payment Arrangements Allocation Of Share Based Compensation Costs By Plan Table [Text Block] Payments of Operating Lease Liability Lessee Operating Lease Liability Maturity Table [Text Block] Third amendment fee received. Gross proceeds from issuance of long-term debt. Summary of significant accounting policy. Schedule of summary of significant accounting policies. Schedule Of Summary Of Significant Accounting Policies [Table] Schedule Of Summary Of Significant Accounting Policies [Table] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative Arrangements And Nonarrangement Transactions [Member] Loan and security agreement. Loan and Security Agreement [Member] Loan And Security Agreement [Member] Research collaboration and license agreement. Research Collaboration and License Agreement [Member] Research Collaboration And License Agreement [Member] Counterparty Name Counterparty Name [Axis] Counterparty Name Repurchase Agreement Counterparty Name [Domain] Western Alliance Bank. Western Alliance Bank [Member] Western Alliance Bank [Member] Ultragenyx Pharmaceutical Inc. Ultragenyx [Member] Ultragenyx Pharmaceutical Incorporation [Member] Long-term Debt, Type Longterm Debt Type [Axis] Long-term Debt, Type Longterm Debt Type [Domain] Term loan. Term Loan [Member] Term Loan [Member] Cystic Fibrosis Foundation Therapeutics, Inc. Cystic Fibrosis Foundation [Member] Cystic Fibrosis Foundation Therapeutics Inc [Member] Product and Service Product Or Service [Axis] Product and Service Products And Services [Domain] LUNAR-CF. LUNAR-CF [Member] L U N A R C F [Member] Underlying agreement. Underlying Agreement [Member] Underlying Agreement [Member] Scenario Statement Scenario [Axis] Scenario Scenario Unspecified [Domain] Disbursement period one. Disbursement Due January 2020 [Member] Disbursement Period One [Member] Disbursement period two. Disbursement Due April 2020 [Member] Disbursement Period Two [Member] Disbursement period three. Disbursement Due July 2020 [Member] Disbursement Period Three [Member] Disbursement period four. Disbursement Due October 2020 [Member] Disbursement Period Four [Member] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] ASC 606 [Member] Accounting Standards Update201409 [Member] Balance Sheet Location Balance Sheet Location [Axis] Balance Sheet Location Balance Sheet Location [Domain] Office and lab space. Office and Lab Space [Member] Office And Lab Space [Member] Summary Of Significant Accounting Policy [Line Items] Summary Of Significant Accounting Policy [Line Items] Gross proceeds from long-term debt agreement Gross Proceeds From Issuance Of Long Term Debt Third amendment fee received Third Amendment Fee Received Total net proceeds through sale of equity securities Proceeds From Issuance Or Sale Of Equity Number of common share exchanged for each purchase common share. Number of ordinary share of company in exchange for each ordinary share Number Of Common Share Exchanged For Each Purchase Common Share Number of operating segment for research and development Number Of Operating Segments Payments for matching funds for remaining budgeted costs. Disbursed amount upon execution of amendment. Disbursement amount payable upon achievement of project goal. Final payment of disbursement amount. Disbursement payment upon achievement of required manufacturing practices and IND application. Contra expense included in research and development expense. Contra expense remaining amount included in accrued expenses. Payments for advance Payments For Advance To Affiliate Payments for matching funds for remaining budgeted costs Payments For Matching Funds For Remaining Budgeted Costs Disbursed amount upon execution of amendment Disbursed Amount Upon Execution Of Amendment Disbursement amount payable upon achievement of project goal Disbursement Amount Payable Upon Achievement Of Project Goal Final payment of disbursement amount Final Payment Of Disbursement Amount Disbursement payment upon achievement of required manufacturing practices and IND application Disbursement Payment Upon Achievement Of Required Manufacturing Practices And I N D Application Contra expense included in research and development expense Contra Expense Included In Research And Development Expense Contra expense remaining amount included in accrued expenses Contra Expense Remaining Amount Included In Accrued Expenses Non-current restricted cash Total cash, cash equivalents and restricted cash shown in the statement of cash flows Dividends declared or paid Dividends Increase in accumulated deficit. Increase in deferred revenue due to adoption of new revenue recognition Increase in accumulated deficit Increase In Accumulated Deficit Operating lease liability Operating Lease Liability Operating lease right-of-use asset Contract with customer asset additions for revenue billings. Contract with customer asset deductions for cash collections. Contract With Customer Liability Additions For Advanced Billings Contract Assets, Balance Contract With Customer Asset Net Additions for revenue billings Contract With Customer Asset Additions For Revenue Billings Contract Assets, Deductions for cash collections Contract With Customer Asset Deductions For Cash Collections Contract Assets, Balance Contract Liabilities, Balance Contract With Customer Liability Contract Liabilities, Additions for advanced billings Contract With Customer Liability Additions For Advanced Billings Additions resulting from adoption of Topic 606 Contract With Customer Liability Change In Timeframe Performance Obligation Satisfied Revenue Recognized Deductions for promised goods/services provided in current period Contract With Customer Liability Revenue Recognized Contract Liabilities, Balance Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions [Table] Collaboration Partner Janssen. Collaboration Partner - Janssen [Member] Collaboration Partner Janssen [Member] Collaboration partner Ultragenyx. Collaboration Partner - Ultragenyx [Member] Collaboration Partner Ultragenyx [Member] Collaboration partner Takeda. Collaboration Partner - Takeda [Member] Collaboration Partner Takeda [Member] Collaboration partner Cure Vac. Collaboration Partner - CureVac [Member] Collaboration Partner Cure Vac [Member] Other collaboration. Other Collaboration [Member] Other Collaboration [Member] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] Total collaboration revenue Option exercise revenue range per target. Upfront payment received. Revenue recognition potential milestone revenue recognized. Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Minimum [Member] Minimum [Member] Maximum [Member] Maximum [Member] Research Collaboration and Exclusive License Agreement. Research Collaboration And Exclusive License Agreement [Member] Research Collaboration And Exclusive License Agreement [Member] Collaboration Partner Janssen [Member] mRNA technology. mRNA Technology [Member] M R N A Technology [Member] Rare disease targets. Rare Disease Targets [Member] Rare Disease Targets [Member] Non-rare disease targets. Non-Rare Disease Targets [Member] Non Rare Disease Targets [Member] Collaboration Partner Cure Vac entered into Co-Development Agreement. Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Collaboration Partner Cure Vac Entered Into Co Development Agreement [Member] Termination agreement. Termination Agreement [Member] Termination Agreement [Member] Other collaboration revenue. Other Collaboration Revenue [Member] Other Collaboration Revenue [Member] Research and exclusive license agreement. Research And Exclusive License Agreement [Member] Research And Exclusive License Agreement [Member] Synthetic Genomics, Inc. Synthetic Genomics, Inc [Member] Synthetic Genomics Inc [Member] Upfront payment received Upfront Payment Received Revenue recognition potential milestone revenue recognized Revenue Recognition Potential Milestone Revenue Recognized Option exercise revenue range per target Option Exercise Revenue Range Per Target Adjustments to transaction price. Remaining performance obligation Revenue Remaining Performance Obligation Adjustments to transaction price Adjustments To Transaction Price Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table] Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Start Date [Axis] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items] Remaining research period Revenue Remaining Performance Obligation Expected Timing Of Satisfaction Period1 Deferred revenue Royalty payment term description. Royalty payment term description Royalty Payment Term Description Number of reserve targets. Option to purchase of additional shares of common stock. Option to purchase of additional shares of common stock price per share. Number of targets Number Of Reserve Targets Purchase of common stock, shares Purchase of additional shares of common stock Option To Purchase Of Additional Shares Of Common Stock Purchase of additional shares of common stock price per share Option To Purchase Of Additional Shares Of Common Stock Price Per Share Collaboration agreement consideration received. Collaboration agreement transaction price. Premium paid for purchase of common stock. Lack of marketability discount restricted period. Consideration received Collaboration Agreement Consideration Received Consideration received for common stock purchase Sale Of Stock Consideration Received Per Transaction Transaction price Collaboration Agreement Transaction Price Premium paid for purchase of common stock Premium Paid For Purchase Of Common Stock Lack of marketability discount restricted period Lack Of Marketability Discount Restricted Period Revenue, practical expedient description Revenue Practical Expedient Remaining Performance Obligation Description Revenue recognition reserve target exclusivity period. Decrease in retained earnings. Cumulative catch up adjustment Contract With Customer Asset Cumulative Catch Up Adjustment To Revenue Change In Estimate Of Transaction Price Revenue recognition, reserve target exclusivity period Revenue Recognition Reserve Target Exclusivity Period Decrease in retained earnings due to adoption of new revenue recognition Decrease In Retained Earnings Development and option agreement date. Development and option agreement date Development And Option Agreement Date Expiration of initial term. Option to extend intial term on an annual basis. Expiration of initial term Expiration Of Intial Term Option to extend intial term on an annual basis Option To Extend Intial Term On An Annual Basis Collaboration agreement termination date. Percentage of global rights reassumed. Collaboration agreement termination date Collaboration Agreement Termination Date Percentage of global rights reassumed Percentage Of Global Rights Reassumed Collaboration agreement settlement obligation one time settled amount. Potential target license term. Collaboration agreement settlement obligation one time settled amount Collaboration Agreement Settlement Obligation One Time Settled Amount Potential target license term Potential Target License Term Upfront fee received. Upfront fee received Upfront Fee Received Collaboration agreement contractual term. Contractual term Collaboration Agreement Contractual Term Cumulative catch up adjustment Contract With Customer Liability Cumulative Catch Up Adjustment To Revenue Modification Of Contract Sublicense revenue recognition. Other collaboration agreement date. Other collaboration agreement date Other Collaboration Agreement Date Sublicense revenue recognized Sublicense Revenue Recognition Prepaid expenses and other current assets. Prepaid Expenses And Other Current Assets [Abstract] Prepaid expenses Prepaid Expense Current Other current assets Other Assets Current Total Property Plant And Equipment [Abstract] Schedule Of Property Plant And Equipment [Table] Schedule Of Property Plant And Equipment [Table] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Research equipment [Member] Equipment [Member] Computer and software [Member] Computer Equipment [Member] Office equipment and furniture [Member] Furniture And Fixtures [Member] Leasehold improvements [Member] Leasehold Improvements [Member] Property Plant And Equipment [Line Items] Property Plant And Equipment [Line Items] Property and equipment, gross Property Plant And Equipment Gross Less accumulated depreciation and amortization Accumulated Depreciation Depletion And Amortization Property Plant And Equipment Property and equipment, net Accrued cystic fibrosis foundation liability. Accrued Liabilities Current [Abstract] Accrued compensation Employee Related Liabilities Current Cystic Fibrosis Foundation Liability (Note 1) Accrued Cystic Fibrosis Foundation Liability Refundable fees received Customer Refund Liability Current Current portion of operating lease liability Operating Lease Liability Current Other accrued liabilities Other Accrued Liabilities Current Total Debt instrument Interest-only repayment period. Debt instrument interest only repayment period extended. Debt instrument amortization period. Debt instrument amortization period for extended interest only period. Debt Instrument [Table] Debt Instrument [Table] Long-term Debt [Member] Long Term Debt [Member] Legal Entity Legal Entity [Axis] Entity Entity [Domain] Ultragenyx Pharmaceutical Inc. Ultragenyx [Member] Ultragenyx Pharmaceutical Inc [Member] Debt Instrument [Line Items] Debt Instrument [Line Items] Loan maturity date Debt Instrument Maturity Date Interest of the prime rate plus Debt Instrument Basis Spread On Variable Rate1 Loan interest payment terms Debt Instrument Payment Terms Loan interest-only payment period Debt Instrument Interest Only Repayment Period Loan interest-only payment period Debt Instrument Interest Only Repayment Period Extended Debt Instrument, amortization period Debt Instrument Amortization Period Debt Instrument, amortization period Debt Instrument Amortization Period For Extended Interest Only Period Warrant fee payable. Loan origination fee paid Unamortized Loan Commitment And Origination Fees And Unamortized Discounts Or Premiums Warrant fee payable Warrant Fee Payable Prepayment fee percentage. Prepayment fee percentage after accepting new drug applications prior to maturity. Percentage of fee liable on principal balance. Fee payable upon repayment. Prepayment fee percentage Prepayment Fee Percentage Prepayment fee percentage Prepayment Fee Percentage After Accepting New Drug Applications Prior To Maturity Percentage of fee liable on principal balance Percentage Of Fee Liable On Principal Balance Fee payable upon repayment Fee Payable Upon Repayment Percentage required to be maintained in deposit and investment account. Debt instrument, collateral Debt Instrument Collateral Percentage required to be maintain in deposit and investment Percentage Required To Be Maintained In Deposit And Investment Account Debt instrument, collateral amount Debt Instrument Collateral Amount Available sale of equity securities Available For Sale Securities Equity Securities Current Stock issued during period Debt instrument interest only payment extended maturity date. Debt instrument interest only repayment maturity date. Term loan Debt Instrument Face Amount Repayments of existing debt Repayments Of Long Term Debt Net increase in indebtedness Proceeds From Issuance Of Debt Loan interest-only payment extended maturity date Debt Instrument Interest Only Payment Extended Maturity Date Loan interest-only payment maturity date Debt Instrument Interest Only Repayment Maturity Date Deposits Deposits Percentage of cash fee on gross proceeds from offering. Schedule Of Stock By Class [Table] Schedule Of Stock By Class [Table] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] Placement agent. H.C. Wainwright & Co., LLC [Member] Placement Agent [Member] Letter agreement. Letter Agreement [Member] Letter Agreement [Member] Securities purchase agreement. Securities Purchase Agreement [Member] Securities Purchase Agreement [Member] Related Party Related Party Transactions By Related Party [Axis] Related Party Related Party [Domain] Investor Investor [Member] Equity purchase agreement. Equity Purchase Agreement [Member] Equity Purchase Agreement [Member] Collaboration Partner Expanded Ultragenyx. Collaboration Partner - Expanded Ultragenyx [Member] Collaboration Partner Expanded Ultragenyx [Member] Registration rights agreement. Registration Rights Agreement Registration Rights Agreement [Member] Vesting Vesting [Axis] Vesting Vesting [Domain] Vested After Obtaining Suitable siRNA License [Member] Share Based Compensation Award Tranche One [Member] Vested After in Vivo Proof-of-concept Achieved [Member] Share Based Compensation Award Tranche Two [Member] Vested After IND Application Completed [Member] Share Based Compensation Award Tranche Three [Member] Share based compensation award tranche four. Vested After in Human Efficacy Achieved [Member] Share Based Compensation Award Tranche Four [Member] Award Type Award Type [Axis] Award Type Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain] Restricted common stock. Restricted Common Stock [Member] Restricted Common Stock [Member] Antidilutive Securities Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis] Antidilutive Securities, Name Antidilutive Securities Name [Domain] Unvested restricted ordinary shares. Unvested Restricted Ordinary Shares [Member] Unvested Restricted Ordinary Shares [Member] Class Of Stock [Line Items] Class Of Stock [Line Items] Percentage of cash fee on gross proceeds from offering Percentage Of Cash Fee On Gross Proceeds From Offering Common stock purchase price per share Sale Of Stock Price Per Share Gross proceeds from offering Common stock, shares issued Sale Of Stock Number Of Shares Issued In Transaction Closing date of offering. Net proceeds from offering after deducting placement agent fees and offering expenses Proceeds From Issuance Of Private Placement Closing date of offering Closing Date Of Offering Percentage of minimum common stock may not exercised total shares outstanding. Percentage of minimum common stock may not exercised total shares outstanding Percentage Of Minimum Common Stock May Not Exercised Total Shares Outstanding Period to register sale of shares. Ownership interest of common stock Sale Of Stock Percentage Of Ownership After Transaction Period to register sale of shares Period To Register Sale Of Shares Stock issued during period shares subject to repurchase option. Share based compensation arrangement by share based payment award option repurchase period from termination date. Number of milestones achieved. Unvested restricted stock shares. Share price of stock issued Share Price Shares subject to repurchase option Stock Issued During Period Shares Subject To Repurchase Option Share based compensation arrangement by share based payment award period from termination date of employee or consultant for repurchase of shares Share Based Compensation Arrangement By Share Based Payment Award Option Repurchase Period From Termination Date Shares vesting percentage Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage Number of milestones achieved Number Of Milestones Achieved Common shares, unvested Unvested Restricted Stock Shares Accelerated ordinary shares vested Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number Modification expense resulting from accelerated vesting of ordinary shares Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost Antidilutive securities excluded from computation of earnings per share Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table] Plan Name Plan Name [Axis] Plan Name Plan Name [Domain] Two thousand eighteen omnibus inactive plan. 2018 Omnibus Equity Incentive Plan [Member] Two Thousand Eighteen Omnibus Inactive Plan [Member] Two thousand nineteen omnibus incentive plan. 2019 Omnibus Equity Incentive Plan [Member] Two Thousand Nineteen Omnibus Incentive Plan [Member] Title of Individual Title Of Individual [Axis] Title of Individual Title Of Individual With Relationship To Entity [Domain] Non executive officer. Non-Executive Officer [Member] Non Executive Officer [Member] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share Based Compensation Arrangement By Share Based Payment Award [Line Items] Share-based compensation number of shares authorized Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized Shares issued in period Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period Common stock reserved for future issuance Common Stock Capital Shares Reserved For Future Issuance Income Statement Location Income Statement Location [Axis] Income Statement Location Income Statement Location [Domain] Research and Development [Member] Research And Development Expense [Member] General and Administrative [Member] General And Administrative Expense [Member] Share-based compensation expenses Allocated Share Based Compensation Expense Lessee Lease Description [Table] Lessee Lease Description [Table] October 2017 lease amendment. October 2017 Lease Amendment [Member] October Two Thousand And Seventeen Lease Amendment [Member] Lessee Lease Description [Line Items] Lessee Lease Description [Line Items] Operating lease extended additional term Lessee Operating Lease Renewal Term Operating lease, remaining lease term Operating Lease Weighted Average Remaining Lease Term1 Lessee, operating lease, term of contract Lessee Operating Lease Term Of Contract Tenant improvement allowance Payments For Proceeds From Tenant Allowance Lessee, operating leases, option to extend Lessee Operating Lease Option To Extend Security deposit Security Deposit 2019 (remaining) Lessee Operating Lease Liability Payments Remainder Of Fiscal Year 2020 Lessee Operating Lease Liability Payments Due Year Two 2021 Lessee Operating Lease Liability Payments Due Year Three 2022 Lessee Operating Lease Liability Payments Due Year Four 2023 Lessee Operating Lease Liability Payments Due Year Five Thereafter Lessee Operating Lease Liability Payments Due After Year Five Total remaining lease payments Lessee Operating Lease Liability Payments Due Less: imputed interest Lessee Operating Lease Liability Undiscounted Excess Amount Total operating lease liabilities Weighted-average remaining lease term Weighted-average discount rate Operating Lease Weighted Average Discount Rate Percent Operating lease costs Operating Lease Cost Schedule Of Related Party Transactions By Related Party [Table] Schedule Of Related Party Transactions By Related Party [Table] Related Party Transaction [Line Items] Related Party Transaction [Line Items] Providence Therapeutics Incorporation. Providence Therapeutics, Inc [Member] Providence Therapeutics Incorporation [Member] Accounts receivable, balance amount Accounts Receivable Related Parties Investment, Name Schedule Of Equity Method Investment Equity Method Investee Name [Axis] Investment, Name Equity Method Investee Name [Domain] ADAIR Technology. ADAIR Technology [Member] A D A I R Technology [Member] Equity method ownership percentage Equity Method Investment Ownership Percentage Share of gain (losses) for investee Equity investments